GB8813527D0 - Bispecific antibodies - Google Patents

Bispecific antibodies

Info

Publication number
GB8813527D0
GB8813527D0 GB888813527A GB8813527A GB8813527D0 GB 8813527 D0 GB8813527 D0 GB 8813527D0 GB 888813527 A GB888813527 A GB 888813527A GB 8813527 A GB8813527 A GB 8813527A GB 8813527 D0 GB8813527 D0 GB 8813527D0
Authority
GB
United Kingdom
Prior art keywords
bispecific antibodies
bispecific
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB888813527A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glennie M J
Original Assignee
Glennie M J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glennie M J filed Critical Glennie M J
Priority to GB888813527A priority Critical patent/GB8813527D0/en
Publication of GB8813527D0 publication Critical patent/GB8813527D0/en
Priority to AU37520/89A priority patent/AU3752089A/en
Priority to EP89906797A priority patent/EP0422043A1/en
Priority to PCT/GB1989/000641 priority patent/WO1989011863A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB888813527A 1988-06-08 1988-06-08 Bispecific antibodies Pending GB8813527D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GB888813527A GB8813527D0 (en) 1988-06-08 1988-06-08 Bispecific antibodies
AU37520/89A AU3752089A (en) 1988-06-08 1989-06-08 Bispecific antibodies
EP89906797A EP0422043A1 (en) 1988-06-08 1989-06-08 Bispecific antibodies
PCT/GB1989/000641 WO1989011863A1 (en) 1988-06-08 1989-06-08 Bispecific antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888813527A GB8813527D0 (en) 1988-06-08 1988-06-08 Bispecific antibodies

Publications (1)

Publication Number Publication Date
GB8813527D0 true GB8813527D0 (en) 1988-07-13

Family

ID=10638262

Family Applications (1)

Application Number Title Priority Date Filing Date
GB888813527A Pending GB8813527D0 (en) 1988-06-08 1988-06-08 Bispecific antibodies

Country Status (4)

Country Link
EP (1) EP0422043A1 (en)
AU (1) AU3752089A (en)
GB (1) GB8813527D0 (en)
WO (1) WO1989011863A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354554A (en) * 1989-02-10 1994-10-11 Celltech Limited Crosslinked antibodies and processes for their preparation
AU6290090A (en) * 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
DE69130561T2 (en) 1990-02-16 1999-06-24 Boston Biomedical Research Institute, Inc., Boston, Mass. Hybrid reagents with the ability to selectively release molecules into cells
IL97459A0 (en) * 1990-03-09 1992-06-21 Hybritech Inc Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5273743A (en) * 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
ZA914625B (en) * 1990-06-22 1993-02-24 Lilly Co Eli In vivo targeting with bifunctional antibodies
US6685930B1 (en) * 1991-03-27 2004-02-03 Tanox, Inc. Methods and substances for recruiting therapeutic agents to solid tumors
US6497881B1 (en) * 1995-11-30 2002-12-24 New York University High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life

Also Published As

Publication number Publication date
EP0422043A1 (en) 1991-04-17
WO1989011863A1 (en) 1989-12-14
AU3752089A (en) 1990-01-05

Similar Documents

Publication Publication Date Title
GB8905669D0 (en) Modified antibodies
GB8608068D0 (en) Monoclonal antibodies
IL90017A0 (en) Monoclonal antibodies
ZA898777B (en) Monoclonal antibodies
GB8621910D0 (en) Monoclonal antibodies
ZA898499B (en) Anti-fucosylcermiade monoclonal antibody
GB8813527D0 (en) Bispecific antibodies
GB8726230D0 (en) Antibodies
GB8616174D0 (en) Monoclonal antibodies
ZA89258B (en) Monoclonal antibodies
GB8820036D0 (en) Monoclonal antibodies
GB8927389D0 (en) Monoclonal antibodies
GB8812137D0 (en) Antibodies
GB8610202D0 (en) Monoclonal antibodies
GB8610203D0 (en) Monoclonal antibodies
EP0423333A4 (en) Anti-endoserine antibody
EP0336441A3 (en) Anti-cpbii monoclonal antibody
GB9318912D0 (en) Humanised antibodies
ZA892882B (en) Monoclonal antibodies
GB8812962D0 (en) Monoclonal antibodies
GB8812963D0 (en) Monoclonal antibodies
GB8820035D0 (en) Monoclonal antibodies
GB8812353D0 (en) Antibodies
ZA891069B (en) Antibodies
GB8718164D0 (en) Monoclonal antibodies